Evoke Pharma gets patent approval extending GIMOTI protection to 2036

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. TMUS
7. AXP
8. DAL
9. VZ
10. SPY

Go back to Evoke Pharma gets patent approval extending GIMOTI protection to 2036

Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036

July 9, 2025 8:16 AM EDT

SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application covering the use of GIMOTI® in patients with moderate to severe symptoms of gastroparesis.

The allowed application is a continuation of U.S. Patent No. 11,517,545, and further expands Evokes intellectual property estate around intranasal... More